1. OPS. La carga de enfermedades renales en la Región de las Américas, 2000-2019. Portal de Datos ENLACE, Organización Panamericana de la Salud. 2021.

2. Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol 2020;16:251.

3. Nogueira A, Pires MJ, Oliveira PA. Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. InVivo 2017;31:1–22.

4. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009;5:319–328.

5. Tammaro A, Stroo I, Rampanelli E, Blank F, Butter LM, Claessen N, et al. Role of TREM1-DAP12 in renal inflammation during obstructive nephropathy. PLoS One. 2013;8(12):e82498. 10.1371/journal.pone.0082498

6. Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, et al. Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther 2014;350 (3):552–562. 10.1124/jpet.114.214205

7. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009;75(11):1145-1152. 10.1038/ki.2009.86.

8. Chevalier RL, Thornhill BA, Forbes MS, Kiley SC. Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. Pediatr Nephrol 2010;25(4):687-97. 10.1007/s00467-009-1316-5.

9. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72. 10.1016/S0140-6736(13)60687-X.

10. Martínez-Klimova E, Aparicio-Trejo OE, Tapia E, Pedraza-Chaverri J. Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments. Biomolecules. 2019;9(4):141. 10.3390/biom9040141.

11. Chen CM, Lin CY, Chung YP, Liu CH, Huang KT, Guan SS, et al. Protective Effects of Nootkatone on Renal Inflammation, Apoptosis, and Fibrosis in a Unilateral Ureteral Obstructive Mouse Model. Nutrients. 2021;13(11):3921. 10.3390/nu13113921.

12. Zou J, Yu C, Zhang C, Guan Y, Zhang Y, Tolbert E, et al. Inhibition of MLL1 ‐menin interaction attenuates renal fibrosis in obstructive nephropathy. FASEB. 2023;37(1). 10.1096/fj.202100634RRR

13. Ucero AC, Benito-Martin A, Izquierdo MC, Sanchez-Niño MD, Sanz AB, Ramos AM, et al. Unilateral ureteral obstruction: beyond obstruction. Int Urol Nephrol. 2014;46(4):765-76. 10.1007/s11255-013-0520-1

14. Hammad FT. The long-term renal effects of short periods of unilateral ureteral obstruction. Int J Physiol Pathophysiol Pharmacol. 2022;14(2):60-72.

15. Wyczanska M, Lange-Sperandio B. DAMPs in Unilateral Ureteral Obstruction. Front Immunol. 2020;11:581300.

16. Tortora, G.J & Derrickson, B. Principios de anatomía y fisiología. 11ª ed. Buenos Aires: Medica Panamericana; 2010.

17. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786-802. 10.1016/S0140-6736(21)00519-5.

18. Zhang JG, Xing ZY, Zha TT, Tian X-J, Du Y-N, Chen J, et al. Longitudinal assessment of rabbit renal fibrosis induced by unilateral ureteral obstruction using two-dimensional susceptibility weighted imaging. J Magn Reson Imaging. 2018;47(6):1572-1577. 10.1002/jmri.25915.

19. Instituto Nacional de Estadísticas y Censos MdSdlN. Tercera Encuesta Nacional de Factores de Riesgo para Enfermedades No Transmisibles. Primera Edición. 2015.

20. Vallejos A MH, Cusumano A. ¿Qué importancia le damos y cómo evaluamos la función renal?. Nefrología Argentina. 2007;5:199.

21. Ministerio de Salud. PROGRAMA NACIONAL DE ABORDAJE INTEGRAL DE ENFERMEDADES RENALES. Ministerio de Justicia y Derechos Humanos – Argentina [Internet]. [2021]. Disponible en: https://servicios.infoleg.gob.ar/infolegInternet/anexos/345000-349999/347584/norma.htm

22. Torales S VA, Valenti L. Hacia un nuevo paradigma en el abordaje de la enfermedad renal crónica avanzada. Rev Argent Salud Pública. 2018;9:33.

23. Chu CD, Powe NR, McCulloch CE, Crews DC, Han Y, Bragg-Gresham JL, et al. Trends in chronic kidney disease care in the US by race and ethnicity, 2012-2019. JAMA Netw Open. 2021;4(9):e2127014. 10.1001/jamanetworkopen.2021.27014.

24. CADRA. Observatorio de Enfermedad Renal Crónica – Análisis base de datos. [Internet]. [2020]. Disponible en: https://www.cadradialisis.org.ar/descargas/SACADIA/Informe_Marzo_2020.pdf

25. Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, et al. Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin Investig Drugs 2018;27(11):917-930. 10.1080/13543784.2018.1538352.

26. Meng XM. Inflammatory Mediators and Renal Fibrosis. Adv Exp Med Biol 2019;1165:381-406. 10.1007/978-981-13-8871-2_18.

27. Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci. 2019;21(1):263. 10.3390/ijms21010263. 

28. Ding Y, Tan Y, Qu Z, Yu, F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2020;42 (1):19-29. 10.1080/0886022X.2019.1702057.

29. Juszczak F, Caron N, Mathew AV, Declèves AE. Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease. Int J Mol Sci. 2020;21 (21):7994. 10.3390/ijms21217994.

30. Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16(5):269-288. 10.1038/s41581-019-0248-y.

31. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238-1252. 10.1016/S0140-6736(16)32064-5.

32. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-40. 10.1038/nm.2807.

33. Kuppe C, Ibrahim MM, Kranz J, Zhang X, Ziegler S, Perales-Patón J, et al. Decoding myofibroblast origins in human kidney fibrosis. Nature. 2021;589(7841):281–6. 10.1038/s41586-020-2941-1. 

34. Farris AB, Alpers CE. What is the best way to measure renal fibrosis?: A pathologist’s perspective. Kidney Int Suppl (2011). 2014;4(1):9-15. 10.1038/kisup.2014.3.

35. Menn-Josephy H, Lee CS, Nolin A, Christov M, Rybin DV, Weinberg JM, et al. Renal Interstitial Fibrosis: An Imperfect Predictor of Kidney Disease Progression in Some Patient Cohorts. Am J Nephrol. 2016;44(4):289-299. 10.1159/000449511.

36. Wang V, Vilme H, Maciejewski ML,  Boulware LE. The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease. Semin Nephrol 2016;36(4):319-30. 10.1016/j.semnephrol.2016.05.008. PMID: 27475662.

37. Chávez-Iñiguez JS, Navarro-Gallardo GJ, Medina-González R, Alcantar-Vallin L, García-García G. Acute kidney injury caused by obstructive nephropathy. Int J Nephrol. 2020;2020:1–10. 10.1155/2020/8846622.

38. Akposso K, Hertig A, Couprie R, Flahaut A, Alberti C, Karras GA, et al. Acute renal failure in patients over 80 years old: 25-years’ experience. Intensive Care Med. 2000;26(4):400-6. 10.1007/s001340051173.

39. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011;6(8):2069-75. 10.2215/CJN.10651110. 

40. Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the Q Kidney Scores. BMC Fam Pract 2010;11:49. 10.1186/1471-2296-11-49. 

41. Stankus N, Hammes M, Gillen D, Worcester E. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res. 2007;35(2):83-7. 10.1007/s00240-007-0079-3.

42. Wongmekiat O, Leelarungrayub D, Thamprasert K. Alpha-lipoic acid attenuates renal injury in rats with obstructive nephropathy. Biomed Res Int. 2013;2013:138719. 10.1155/2013/138719.

43. Docherty NG, Morales AI, Lopez Novoa JM, Perez Barriocanal F. La transición de células epiteliales a miofibroblastos. mecanismos involucrados y su posible relación con la fibrosis renal. Nefrología. 2007;27(6):661–804.

44. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69(2):213-7; 10.1038/sj.ki.5000054.

45. Nagle RB, Bulger RE, Cutler RE, Jervis HR, Benditt EP. Unilateral obstructive nephropathy in the rabbit. I. Early morphologic, physiologic, and histochemical changes. Lab Invest. 1973;28(4):456-67.

46. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;283(5):F861-75; 10.1152/ajprenal.00362.2001.

47. Hesketh E.E, Vernon MA, Ding P, Clay S, Borthwick G, Conway B, et al. A Murine Model of Irreversible and Reversible Unilateral Ureteric Obstruction. J. Vis. Exp. 2014 (94), e52559; 10.3791/52559.

48. Prieto M, Rodríguez-Peña AB, Düwel A, Rivas JV, Docherty N, Pérez-Barriocanal F, et al. Temporal changes in renal endoglin and TGF-beta1 expression following ureteral obstruction in rats. J Physiol Biochem. 2005;61(3):457-67. 10.1007/BF03168452.

49. Nørregaard R, Mutsaers HAM, Frøkiær J, Kwon TH. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis. Physiol Rev. 2023;103(4):2827-2872. 10.1152/physrev.00027.2022

50. Tseng TY, Stoller ML. Obstructive uropathy. Clin Geriatr Med. 2009; 25(3):437-43. 10.1016/j.cger.2009.06.003.

51. Yaxley J, Yaxley W. Obstructive uropathy – acute and chronic medical management. World J Nephrol. 2023;12(1):1-9. 10.5527/wjn.v12.i1.1.

52. Leuba C, Said C, Stucker F, Zender H, John G. Le syndrome de levée d’obstacle, vu par l’interniste [Post-obstructive diuresis, by the internal physician]. Rev Med Interne. 2023;44(5):253-258. 10.1016/j.revmed.2023.01.011.

53. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins y Cotran Patología estructural y funcional. 8.ª ed. Barcelona: Elsevier; 2010.

54. Schreibing F, Anslinger TM, Kramann R. Fibrosis in Pathology of Heart and Kidney: From Deep RNA-Sequencing to Novel Molecular Targets. Circ Res. 2023; 132(8):1013-1033. 10.1161/CIRCRESAHA.122.321761.

55. Portilla D, Xavier S. Role of intracellular complement activation in kidney fibrosis. Br J Pharmacol. 2021;178(14):2880-2891. 10.1111/bph.15408.

56. Klahr S. Obstructive nephropathy. Kidney Int. 1998;54(1):286-300.